• Chris Bunka, CEO of LXRP, in an interview with CFN Media Group, stated that his company’s cash flow is strengthening from licensing and R&D, with technology applicable to other sectors
• Bunka noted that LXRP’s 71 million share count is kept purposely low relative to others in the category, with its valuation growing by “close to 2,000 percent” over the past several years
• LXRP’s goal is to slow disease and make cannabis acceptable to the general population

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in value and cash flow, purposely keeping its cash burn rate down and evaluating technology applications for both cannabis and other sectors (http://ibn.fm/6gBzv).

Bunka explained that LXRP is respecting its shareholders in terms of lowered spending and increasing its valuation, purposely maintaining its outstanding share count at relatively low levels. He said that LXRP is building its cash flow through licensing and R&D, as its technology can be used in other sectors besides cannabis. The company is focused on cannabinoid delivery R&D with its DehydraTECH™ technology, which enhances the performance of beneficial compounds in ingestible products, but it can be used across multiple categories, such as nicotine absorption. The result of all this, according to Bunka, is investors that are respected and a valuation of the company that has grown “by close to 2,000 percent’ in recent years.

Based in British Columbia, Canada, LXRP out-licenses its disruptive delivery technology that promotes healthier ingestion methods, resulting in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.

The company’s patented DehydraTECH™ is key to LXRP’s valuation. “We believe that infused foods should taste more like food and less like marijuana,” Bunka noted in the interview. “Our consumers find their coffee tastes a bit more like coffee and less like cannabis, and additionally notice that the cannabinoids take effect faster, and they feel a different type of effect than the typical edible. For medical patients who medicate often, that difference means a lot.”

Bunka explained that, within the tobacco and nicotine industry, recent lab tests have shown a 50 percent improvement in nicotine absorption into the bloodstream of rats with its technology, as compared to a control group. It found even higher percentage levels – 560 percent – of nicotine absorbed in brain tissue. It was a surprising result that might lead to development of cigarette smoking-cessation products by satisfying cravings for nicotine for extended periods of time. He said that these results, if replicated in human trials, could have a profound impact on treatment of cancer and brain tumors in the pharmaceutical and biotech sectors, making Lexaria’s technology a candidate for much more than cannabis applications.

The company’s patent portfolio is growing. It already has more than 40 patent applications or awards in more than 40 countries. Late last year, LXRP received its first U.S. patent on nicotine, ibuprofen and aspirin delivery, as well as cannabinoids. Bunka explained that the company is in the “active investigation phase” in the EU, Canada, China, Japan and India for more patents. “We’re filing new patent applications all the time,” he added.

For more information, visit the company’s website at www.LexariaEnergy.com

• CIIX’s strategy is to blanket Chinese-speaking population in America with daily cryptocurrency broadcast from NYSE, podcast, online site, ATMs, mining operation and educational courses
• Bitcoin and blockchain show is on Phoenix North America Chinese Channel and will also be broadcast online at NewCoins168.com, CIIX’s website, and its YouTube channel
• CIIX has established a cryptocurrency mining operation and signed an LOI to acquire the assets of XBTeller.com for some $2.5 million; that company has nine Bitcoin ATMs in Colorado

ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a new 22-minute monthly TV program titled ‘Bitcoin Talk Show’, which it expects will reach more than 500,000 Chinese-speaking individuals through the Phoenix North America Chinese Channel. It will also be seen on the company’s YouTube and ChineseFN channels, as well as CIIX’s online site, NewCoins168.com (http://ibn.fm/mvqIx). CIIX has signed an LOI to acquire bitcoin ATM operator XB Teller.com (http://ibn.fm/TtIgi), and it has entered a licensing partnership with ‘The Bad Crypto Podcast’ to rebroadcast some of its most popular shows in Chinese (http://ibn.fm/du8m5).

All of this activity reinforces CIIX’s strategy of educating then broadcasting, by internet, cable TV and podcast, news about bitcoin and other cryptocurrencies to its targeted Chinese-speaking audience. The Bitcoin Talk Show will broadcast on the Direct TV and EchoStar satellite systems in both traditional and simplified Chinese. Through Time Warner Cable, the show is expected to reach more than 500,000 in the U.S. alone, CIIX said. That figure is a significant share of the estimated 3.3 million Chinese-speaking people in the U.S., according to the Census Bureau back in 2010 (http://ibn.fm/UUEcy).

CIIX is a diverse educational and consulting company aimed at the Chinese-speaking community located in China and the U.S. Its primary revenue streams have been from subscriptions and investor relations. Most recently, it has offered educational and sales services in cryptocurrency, particularly bitcoin. CIIX’s goal is to become the leading Chinese publicly-traded company that offers real-time information. It projects a 30 percent revenue gain in its fiscal year ended May 31, 2018 (http://ibn.fm/GxfoN).

CIIX has already established itself as a primary and diverse provider of cryptocurrency education to the Chinese-speaking population globally and, specifically, in North America. Not only does it own a daily video broadcast from the NYSE called ‘Bitcoin MultiMillionaire’; it also hosts a Bitcoin ATM in the lobby of its San Gabriel, California, headquarters. The company has acquired ASIC machines and is mining for virtual currency in a datacenter near Seattle.

For more information, visit the company’s website at www.ChineseInvestors.com

• AnalytixInsight’s first-quarter report notes 200 percent jump in year-over-year revenues
• Market analysts foresee big data industry reaching $84 billion level by 2024
• Company’s partners include European bank Intesa Sanpaolo, multi-national media giant Thomson Reuters

Building on a year of growth that led to its designation as “one of the top 10 performing technology companies in the 2018 Venture 50” with a market cap change of 288 percent on the Canadian TSX exchange (http://ibn.fm/fdPkl), artificial intelligence data delivery company AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is off to a strong start for 2018 with a 200 percent-plus increase in revenue year-over-year, as noted in its first-quarter financial results reported on May 30 (http://ibn.fm/0JphQ). While companies worldwide strive to build success and weather market uncertainties, AnalytixInsight has found appeal with those seeking a measure of security in the form of data-driven analysis on the competition, as well as the companies’ internal systems.

AnalytixInsight’s AI-based fintech platform CapitalCube is finding licensees among leading financial news agencies, web portals and stock exchanges. Amid the modern era’s insatiable desire for actionable information that crosses national borders and continental divides, CapitalCube culls information on more than 50,000 globally listed stocks and North American ETFs (exchange-traded funds), producing 100 billion daily computations.

The information industry can be profitable. Market analysts at Statista predict that revenues generated by the big data and business analytics industry will jump 100 percent from their estimated $42 billion level this year to $84 billion in six years (http://ibn.fm/bNkk2). The trend bespeaks the transformative power of technology on a business’s bottom line.

AnalytixInsight’s report notes that it closed the quarter with revenues of $1.01 million and operating capital of $1.82 million.

Euronext, the leading pan-European exchange in the Eurozone, has embedded the company’s analytics tech within its “Market Insight” app, which is being deployed as a real-time stock trading solution. AnalytixInsight’s subsidiary, MarketWall, has also embedded the company’s analytics content within its MarketWall app, which is expect to be rolled out later this year by Italy’s largest retail bank, Intesa Sanpaolo. The bank has 12.6 million customers across Europe.

Thomson Reuters, a media company that has provided information for the world’s professional markets for over a century, completed a research distribution agreement with CapitalCube early in the quarter, through which Thomson Reuters will supply AnalytixInsight’s machine-learning platform with information and then distribute the resulting product to customers via financial desktop applications Eikon and Thomson One. The distribution of AnalytixInsight’s financial research reports will be implemented in phases, beginning late in 2018.

“We are making great progress with our existing strategic partners and we are working with more potential new partners. Both the financial and workforce management industries are quickly embracing machine-learning, and we are witnessing a shift in thinking as industry participants now look to incorporate machine-learning into their business solutions,” AnalytixInsight president and CEO Prakash Hariharan stated in summation of the quarterly report.

For more information, visit the company’s website at www.AnalytixInsight.com

• Focused on California, the largest legal cannabis market in North America
• Operates an attractive royalty model that is beneficial for operators and the company
• Established partnerships with best-in-class operating entities
• Extensive network provides access to top-tier projects and operators
• Executive leadership team with 40+ years of combined experience in fund raising, capital management, corporate development, merchant and commercial banking

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

For more information, visit the company’s website at www.FinCannaCapital.com

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

• Social media app that harnesses enthusiasm for sports
• Novel marketing campaign with hashtag #WearYourColors
• Investment banking executive joins as financial advisor

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) is doing for sports fans today what the Circus Maximus did for ancient Romans. At this largest of Roman hippodromes (horse racing tracks), some 2,000 feet long and 600 feet wide, spectators were treated to captivating contests that typically featured 12 four-horse chariots racing for four miles as they traversed the Circus’ circumference seven times. The passion and excitement of 250,000 fans, the hippodrome’s seating capacity, as they cheered their favorites on must have made for a deafening din that’s unheard of today. The largest football stadium in America seats just around 100,000. Nevertheless, today’s fans are just as passionate, which is why FANDOM SPORTS, through its social media Android Sports App, is providing a platform for them to express their exuberance and frustration, just as the Circus did for its toga-clad enthusiasts.

Ancient Romans were possessed of the same fervor that might be witnessed at any modern game of football or baseball, which prompted the poet Juvenal to remark that they cared only about ‘bread and circuses’. Other striking similarities exist. Just as today’s sport figures can earn six-figure incomes, another contemporary commentator (the poet, Martial) complained about the huge sums (15 bags of gold) that a winning charioteer might ride off with. The most successful of them all, Diocles, is estimated to have made about 36 million sesterces (about $50 million in today’s money) over the course of his career. So, over a millennium, neither sports fans nor sports seem to have changed much. Our instincts of playfulness and competitiveness appear to go very far back.

Recognizing that basic truth, FANDOM SPORTS has developed the Android Sports Mobile App to give sports fans around the world an uncensored social media platform that will allow them to express their primal, unfiltered passions. The App brings fans together in a very modern setting, the social media environment, which, today, is increasingly rivaling traditional forums of physical interaction. The App is designed to entertain sports enthusiasts with interactive content that offers bragging rights and real-life rewards. True sports addicts will appreciate the App, which allows fans to pick a fight, create their own FanFights or rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishing consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Recently, FANDOM SPORTS launched a new campaign to reward fans who celebrate their teams with creative tattoos and body art. The interactive campaign, with the hashtag #WearYourColors, will identify and reward the most passionate sports fans.  The campaign will kick-off to coincide with the month-long soccer tournament in Russia; it will seek to discover the fans with the most “artistically expressive” tattoos or body art. Winners will get two tickets to any sporting event of their choosing in the U.S. or Canada (http://ibn.fm/dEhqZ).

Additionally, FANDOM SPORTS has engaged the services of Vikas Ranjan, founder and current president of Gravitas Financial Inc., a Toronto-based investment holding and merchant banking firm. Vikas has over 22 years’ experience in diverse areas of finance, capital markets, investments, entrepreneurship and management consulting. His global expertise ranges internationally and includes familiarity with emerging economies, like India, where FANDOM SPORTS expects its App to be well received (http://ibn.fm/sMEpR).

Before co-founding Gravitas Financial, Vikas was the co-founder of Ubika Research, an investment research and capital market services firm. He was also the co-founder of SmallCapPower.com, a leading online portal for small cap investments. His previous experience also includes various management positions with companies such as TAL Global Asset Management and the Bank of Montreal.

For more information, visit the company’s website at www.FANDOMSPORTS.net

• Discovers undervalued real estate investments with the potential for high rate of return
• Economic potential for Montenegro as it partners with NATO and seeks to join the EU
• Investment in two beachside developments in Tivat, Montenegro

American-Swiss Capital, Inc., headquartered in Miami, Florida, is a company focused on seeking quality and undervalued real estate investments to create a high rate of return. The company’s experienced management team possesses the knowledge and skills required to consistently provide accurate and reliable research specifically designed to identify the safest and most profitable investment opportunities. American-Swiss Capital is positioned as a conduit between U.S. equity markets and leading enterprises in Switzerland and Northern Europe. Currently, the company is focused on beachfront property in the small nation of Montenegro.

Montenegro is a tourist destination boasting 45 miles of beaches and drawing in more tourists in 2017 than the total of the country’s population (http://ibn.fm/uT2iI). This tourism has played a large part in the positive gains seen in the last year to the country’s economy. Montenegro is making positive strides as it seeks to join the European Union and further strengthen the country’s economy and reputation. June 4, 2018, marked one year since Montenegro’s accession to NATO.

“Just as Montenegro is stepping up for NATO, NATO is stepping up for Montenegro,” NATO Secretary General Jen Stoltenberg stated during a joint press conference earlier this month. “NATO is a defensive Alliance. We protect all Allies against any threat. So [June 5, 2018], NATO will begin air policing patrols over Montenegro, with jets from Italy and Greece. This peacetime mission will ensure the safety of your skies, whether from civilian or military aircraft in distress, or any other threat. NATO provides this support to Allies without their own air forces – a strong sign of NATO solidarity” (http://ibn.fm/b2y7B).

The world is taking notice of Montenegro, and so is American-Swiss Capital. The company is in negotiations to buy an 18-unit beachfront apartment complex with a private beach and a fixed pontoon boat berth in the Boka Bay community of Tivat, a popular tourist destination. A second project is to construct 30 villas in the Kovac Gated Community directly on Tivat Bay with views of St. Marko Island. American-Swiss Capital sees the potential of a country being noticed by leaders and tourists worldwide.

For more information, visit the company’s website at www.AS-Capital.com

• Lexaria has its patented DehydraTECH™ nutrient infusion technology
• This technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids
• DehydraTECH™ technology provides greater bio-absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. This technology significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other beneficial molecules. Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria has patents granted in the United States and Australia for applications of its DehydraTECH™ technology. In addition, it has numerous patents pending in more than 40 countries. Issued and pending patents name a wide spectrum of lipophilic bioactives and food/carrier particles that can be formulated and delivered using the company’s DehydraTECH™ technology.

The company’s technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids. In December 2017, the company received its first patent from the U.S. Patent Office, which covers nicotine, ibuprofen and aspirin delivery, along with cannabinoids.

In the cannabis business, Lexaria’s focus is to make infused foods taste more like food and less like marijuana, while providing many other benefits.  Fundamentally, the DehydraTECH™ technology makes it possible to transport bioactive substances by way of oral ingestion. DehydraTECH™ does so without the need for inhalational dosing. The technology also enhances the flavor and bouquet of cannabinoid edibles.

A major feature of DehydraTECH™ technology is that dosing doesn’t have to be combined with unhealthy sugars or sweeteners upon administering. Sugars and sweeteners are typically used to mask harsh tastes. The DehydraTECH™ delivery method removes the need for sugar-filled food. DehydraTECH™ features flavor-masking for poor tasting compounds.

The technology also reduces the time of onset of THC (tetrahydrocannabinol) effects. Moreover, it provides greater bio-absorption. Cannabinoids are usually poorly absorbed by the gastrointestinal system. However, Lexaria Biosciences’ DehydraTECH™ increases absorption by five to 10 times, which is equal to that of inhalation. Oral ingestion is also safer than inhalation with devices and involves fewer complexities.

The U.S. National Library of Medicine – National Institutes of Health notes in its article, ‘Inhalation Drug Delivery Devices: Technology Update’, that, “The major problems with the use of inhaler devices are the deposition of aerosolized particles in the oropharyngeal region and upper airways and the lack of coordination between the device activation and inhalation due to lack of patient training” (http://ibn.fm/QqAXW).

The company’s technology also provides protection during stomach transit. Furthermore, DehydraTECH™ bypasses first pass liver effect. The small intestine quickly absorbs LCFAs (Long-Chain Fatty Acids) into the lymphatic system and MCFAs (Medium-Chain Fatty Acids) through the liver.

Recently, Lexaria Bioscience announced lab test results regarding the delivery of nicotine via the gastrointestinal tract and first-rate nicotine absorption in animal blood plasma. The results show rapid speed of onset and bioavailability. These results have led to more and continuing dialogue with foremost nicotine industry participants concerning the possible use of the company’s technology for a smoke-free nicotine outlook. However, Lexaria is not partnering with the tobacco industry.

Lexaria’s DehydraTECH™ technology crosses the intestinal wall very effectively. The company is also studying if it affects blood-brain barrier transmission. If it does, Lexaria says that it has the potential to have major outcomes for biotechnology and pharmaceuticals along with cannabis.

For more information, visit the company’s website at www.LexariaEnergy.com

• PreveCeutical moves on recent stock split to boost share appeal
• Company’s organic therapeutics aim to relieve maladies for patients with diabetes, brain injuries and other conditions
• Alternative medicines market expected to generate nearly $200 billion in revenues by 2025

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) continues working to shore up its share appeal while seeking remedies for a variety of physical ailments through its nature-centric research to help patients with type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.

PreveCeutical Medical completed a forward stock split last month on the basis of five new shares per one existing share, which resulted in a corresponding forward split of millions of common share purchase warrants issued following a non-brokered private placement last year (http://ibn.fm/MObzY). The 20.28 million (4.07 million pre-split) common share purchase warrants issued after the June 2017 financing measure allowed holders to buy into the company at a price of $1 per share during the 12 months after the warrants were issued. The expiry date is being extended by an additional 12 months to facilitate their conversion (http://ibn.fm/DPJWn).

The warrant extension will also allow holders to buy shares at a price of $0.20 per share until June 29, 2019. An exception clause allows the company to accelerate the expiration date for exercising the warrants, with 14 business days’ notice, if the closing price of the shares on the Canadian Securities Exchange is at least $0.30 or more for 10 consecutive business days.

“We believe the Stock Split demonstrates the Company’s continued commitment to broaden its shareholder base and we anticipate that the Stock Split will make PreveCeutical’s securities more accessible to investors and enhance liquidity for shareholders,” CEO, president and board chairman Stephen Van Deventer stated in a news release.

PreveCeutical is a company dedicated to providing medical patients with natural and nature-inspired formulations to treat select maladies and help prevent them from occurring. The company has five research and development programs under way and expects to partner with other companies to fund clinical trials once proof of concept has been sufficiently developed (http://ibn.fm/ptWCS).

One area of focus for PreveCeutical has been to make non-psychoactive cannabis product CBD bioavailable to patients through the best means possible, which means enabling it to reach the brain by circumventing the digestive system’s friable processes. Through PreveCeutical’s Sol-gel nasal delivery system, the medication would be able to reach the brain directly through the blood-brain barrier.

The company recently announced that it has signed a non-disclosure agreement with a leading drug delivery device manufacturer to work with the Sol-gels (http://ibn.fm/B2dAg) in preparation for a marketable solution. Earlier this month, PreveCeutical announced an agreement with Stadnyk & Partners to obtain strategic finance and marketing advisory services that will help the company achieve its business growth goals (http://ibn.fm/m9ijw).

PreveCeutical’s drive to develop its Nature Identical line of biopharmaceuticals positions it to take advantage of the mainstreaming of the complementary and alternative medicine market, a sector that’s expected to generate $196.87 billion in revenues by 2025, according to a report by Grand View Research, Inc. (http://ibn.fm/SId04). The market has been driven by the popularity of herbal dietary supplements and other wellness therapies like yoga and acupuncture, but the recent global clamor for legal cannabis-derived products has sparked an explosion in market expectations. Research analyst company Brightfield Group expects the CBD market to reach $1 billion early in the next decade (http://ibn.fm/j1efl). Women’s Marketing, which collaborated with Rodale on original consumer research into the modern “Health and Wellness” consumer mindset, labels wellness “the new black” that has become a status symbol among consumers. The company’s report argues that women in the United States alone invest $40 billion into alternative medicine (http://ibn.fm/k4YQq).

For more information, visit the company’s website at www.PreveCeutical.com

• Equity swap further boosts Pressure BioSciences’ plans to uplist to a major stock exchange later this year
• Latest deal brings total debt-to-equity conversions to over $13.6M in past 30 days
• 2015/2016 debentures, line-of-credit and promissory note, plus various short-term debt, now converted to equity
• Company’s recently acquired Pre-EMT™ platform, allowing for improved protein-based drug development, has significant market potential and adds to a string of technological developments

Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step forward as yet another group of debt holders have agreed to a debt-to-equity swap, this time amounting to $7.24 million, representing a strong message of investor support. The total amount of debt that has been converted to equity is now over $13.6 million, all in just the past four weeks (http://ibn.fm/NZQeN).

In a news release, Joseph L. Damasio, the company’s VP of finance and CFO, said, “With today’s announced conversion of an additional $7.24M of debt to equity, total loan debt has been reduced from approximately $16.6M to approximately $3.0M, an amount that we believe is manageable by PBI. We are continuing to talk to the remaining debt holders and have reason to believe that several more may follow the lead of the approximate 40+ debt holders who have converted their debt into equity over the past 30 days. If they do, we believe the amount of loan debt on our Balance Sheet could decrease by an additional 10-20%.”

Jeffrey N. Peterson, chairman of the board of directors, added, “We believe PBI’s recent accomplishments, when combined with the conversion of the majority of our loan debt into equity, will materially enhance our stated objective of uplisting to a national exchange (NASDAQ, NYSE/Amex) later in 2018, which should result in a more stable, attractive, and valuable company for all shareholders.”

This announcement follows a long list of positive news for the company, including first quarter revenue growth and the agreement of an earlier $6.39 million debt-to-equity swap with the company’s 2015/2016 Convertible Debenture Holders, made public on May 18, 2018 (http://ibn.fm/Gyw7s).

Pressure BioSciences develops and produces life sciences laboratory tools based on its pioneering Pressure Cycling Technology (PCT). This patented technology is a powerful instrument that enables scientists to prepare biological samples for use in a wide range of fields, including biomarker discovery, pathology, forensics and agriculture.

The company’s PCT systems, including instruments and related consumables, are in use throughout the U.S., Canada, Europe, Australia, Japan and China, with 300 systems set up in more than 150 labs. The PCT system boasts a number of advantages over other methods, including better DNA detection and improved extraction of cell membrane and other proteins.

Pressure BioSciences is also in collaboration with Phasex Corporation to create water-soluble nanoemulsions, which could have wide-ranging uses in pharmaceutical research and development, cosmetics, food production and various industrial applications (http://ibn.fm/LZ8Hm).

Phasex develops separation processes for extracting various compounds, natural extracts and chemicals using its supercritical fluid (SCF)-based toll processors. By combining Phasex’s extraction methods and PBI’s Ultra Shear Technology (UST) – an innovative technique based on the use of intense shear forces generated by ultra-high pressure – the companies expects to develop stable nanoemulsions that will be of significant commercial interest.

Emulsification refers to the process by which liquids that cannot ordinarily be blended together are held in a mixture, usually with the addition of another chemical, known as a surfactant or an emulsifier. Nanoemulsions allow extremely tiny droplets of one liquid to be mixed with another. Because the droplets are so small, nanoemulsions allow a larger amount of so-called “hydrophobic” liquids to be mixed with water. When used in medicine, this could mean that the nanoparticles are more readily absorbed into the body, resulting in treatments that are more effective. The applications extend beyond medicine to a number of other industries.

With its Ultra Shear Technology, Pressure BioSciences can reduce the need to add surfactants while creating nanoemulsions, which should lead to a purer compound with fewer additives and greater stability.

The company is also optimistic about the market potential of yet another one of its groundbreaking technologies: the Pre-EMT™ platform, which helps pharmaceutical companies create protein-based medicines, and it has already attracted interest from the pharmaceutical industry. Pressure BioSciences acquired Pre-EMT™ when it recently bought all of the assets of BaroFold, Inc., the previous owners of the technology.

Since the acquisition, Pressure BioSciences has entered into a contract with a drug company interested in using Pre-EMT™ to develop protein-based therapeutics, and more deals are in the pipeline (http://ibn.fm/LNNpX).

For more information, visit the company’s website at www.PressureBioSciences.com

• Green is a FinCEN compliant payment processing platform for those in the cannabis industry
• Constant changes within the cannabis industry, as states and the federal government work to define new laws
• SpeedyGrow partnering with local hemp farmers in the Grand Valley to help boost the community’s economy

Medical Cannabis Payment Solutions (OTC: REFG), a financial services company directed at the medical cannabis and banking industries, has been filling the gap for cannabis providers who lack bank support due to federal regulations by providing online banking solutions. First offered only to medical cannabis merchants, the company’s services are now available to the entire cannabis industry through its innovative Green platform. The Green platform allows for electronic payments and secure cash deposits, all while remaining FinCEN compliant. REFG keeps clients in compliance and bears the proof of burden, freeing clients to focus on everything else that goes into running a successful business.

Changes are constantly occurring within the cannabis industry, and REFG stays on top of the changes, making sure that the banking solutions it provides are up-to-date. It is no easy task to stay up-to-date on the changing laws and regulations. Last week, President Trump stated that he was likely to back a marijuana bill to leave the decision of legalization to the states, a remark in direct contrast to the policies backed by Attorney General Jeff Sessions. “It means right now, that for example, in Colorado , and soon in Massachusetts, someone who buys marijuana, someone who sells marijuana is complying with state law, but they are in violation of federal law. And that puts them at risk,” Senator Elizabeth Warren, one of two who introduced the bill, remarked regarding laws as they stand (http://ibn.fm/zX95w). It’s no wonder that traditional banks are hesitant to tackle the unique challenges of this industry as the states and federal government work to define new laws. The Green platform adapts to the changes in compliance, offering the only real solution for cannabis dispensaries who no longer wish to run the risk of operating on a cash-only basis.

While the courts hash out the legalities, REFG has its eyes on the future as it invests in local communities. The CBD extraction facility SpeedyGrow Inc., a subsidiary of REFG, was recently featured on KREX, the CBS-affiliated television station in Grand Junction, Colorado. The news story provides a small tour of the facility and discusses the company’s efforts in CBD extraction. SpeedyGrow is partnering with local hemp farmers every step of the way. During the planting season, the company provides the farmers with Speedy Veg, an organic growth supplement.

After harvesting, farmers no longer need to ship their product four to five hours away to Denver. The full process is now done locally, reducing the cost to farmers which then in turn passes on cost savings to the consumer. The company does not charge farmers for the process of extraction but instead shares the revenue on the back end. The CBD oil is sold in its raw form or turned into products like soft gels or tinctures. “We have embraced being a part of the community and are excited to be a part of a growing segment of the community’s economy,” stated David Schenk, co-owner of Speedy Grow Inc., who sees this process as holding the potential for an economic boom for the area. “We believe this valley can be known for the highest quality CBD anywhere in the nation. That people seek out the flower that’s grown here.” It’s a sentiment that is shared by local farmers (http://ibn.fm/MOIGx).

For more information, visit the company’s website at www.Take.Green